Recent innovative research in our division includes:
- the development of new approaches for identifying markers of non-alcoholic liver fatty disease,
- intravital study of hypothalamic regulation of appetite,
- studies of genes associated with bone mineral density defects and susceptibility to diabetes,
- innovative chemistry for the development of safer tocolytics (labor repressants) and the identification of new genes and regulators of adipogenesis and insulin resistance.
Such research should allow understanding weight gain and better target obesity-related problems, which underlies diabetes, and identifying new clinical targets for prevention of such conditions. Genetic and proteomic studies should also allow identifying new predictors and clinical targets for the prevention of obesity, diabetes and bone diseases.
Research being currently conducted includes:
- conditions related to nutrition, obesity and diabetes,
- metabolism of muscle and bone in both aging and disease conditions,
- reproductive endocrinology,
- cellular mechanisms by which hormones, steroids and drugs exert their functions in endocrine tissues,
- genomic and proteomic studies of metabolic diseases for identifying new clinical targets and biomarkers for diagnostics,
- the identification of new pharmacological targets and the development of novel therapies,
- the impact of nutrition on endocrine function.